338 related articles for article (PubMed ID: 23038259)
1. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
[TBL] [Abstract][Full Text] [Related]
2. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
3. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.
Liu Y; Sánchez-Tilló E; Lu X; Huang L; Clem B; Telang S; Jenson AB; Cuatrecasas M; Chesney J; Postigo A; Dean DC
J Biol Chem; 2014 Feb; 289(7):4116-25. PubMed ID: 24371144
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
5. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
7. Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73.
Lu Z; Jiao D; Qiao J; Yang S; Yan M; Cui S; Liu Z
Mol Cancer; 2015 May; 14():102. PubMed ID: 25972084
[TBL] [Abstract][Full Text] [Related]
8. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
Ma S; Jiang B; Deng W; Gu ZK; Wu FZ; Li T; Xia Y; Yang H; Ye D; Xiong Y; Guan KL
Oncotarget; 2015 Apr; 6(11):8606-20. PubMed ID: 25825982
[TBL] [Abstract][Full Text] [Related]
9. Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes.
Zhao S; Zhang Y; Zheng X; Tu X; Li H; Chen J; Zang Y; Zhang J
J Cell Physiol; 2015 Nov; 230(11):2706-17. PubMed ID: 25808945
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction.
Lu J; Li D; Zeng Y; Wang H; Feng W; Qi S; Yu L
J BUON; 2019; 24(6):2458-2464. PubMed ID: 31983120
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells.
Tian Y; Pan Q; Shang Y; Zhu R; Ye J; Liu Y; Zhong X; Li S; He Y; Chen L; Zhao J; Chen W; Peng Z; Wang R
J Biol Chem; 2014 Dec; 289(52):36101-15. PubMed ID: 25371200
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.
Dong P; Karaayvaz M; Jia N; Kaneuchi M; Hamada J; Watari H; Sudo S; Ju J; Sakuragi N
Oncogene; 2013 Jul; 32(27):3286-95. PubMed ID: 22847613
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-126 Inhibits Proliferation, Migration, Invasion, and EMT in Osteosarcoma by Targeting ZEB1.
Jiang R; Zhang C; Liu G; Gu R; Wu H
J Cell Biochem; 2017 Nov; 118(11):3765-3774. PubMed ID: 28379605
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells.
Baud J; Varon C; Chabas S; Chambonnier L; Darfeuille F; Staedel C
PLoS One; 2013; 8(4):e60315. PubMed ID: 23565224
[TBL] [Abstract][Full Text] [Related]
17. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.
Castilla MÁ; Moreno-Bueno G; Romero-Pérez L; Van De Vijver K; Biscuola M; López-García MÁ; Prat J; Matías-Guiu X; Cano A; Oliva E; Palacios J
J Pathol; 2011 Jan; 223(1):72-80. PubMed ID: 21125666
[TBL] [Abstract][Full Text] [Related]
18. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
20. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.
Ohashi S; Natsuizaka M; Naganuma S; Kagawa S; Kimura S; Itoh H; Kalman RA; Nakagawa M; Darling DS; Basu D; Gimotty PA; Klein-Szanto AJ; Diehl JA; Herlyn M; Nakagawa H
Cancer Res; 2011 Nov; 71(21):6836-47. PubMed ID: 21890822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
